Tildrakizumab, CAS 1326244-10-3

Product Description: Tildrakizumab (SCH 900222) is a humanized anti-IL-23 (p19 subunit) monoclonal antibody. IL-23 is a critical cytokine to maintain the Th17 cell phenotype. Tildrakizumab has high-affinity for single-chain IL-23 (Kd: 136 pM). Tildrakizumab is effective against moderate to severe plaque psoriasis[1][2][3].

Applications: COVID-19-immunoregulation

Formula: N/A

References: [1]Papp K, et al. Tildrakizumab (MK-3222), an anti-interleukin-23p19 monoclonal antibody, improves psoriasis in a phase IIb randomized placebo-controlled trial. Br J Dermatol. 2015 Oct;173(4):930-9. /[2]Zhou L, et al. A non-clinical comparative study of IL-23 antibodies in psoriasis. MAbs. 2021 Jan-Dec;13(1):1964420. /[3]Santostefano M, et al. Nonclinical safety of tildrakizumab, a humanized anti-IL-23p19 monoclonal antibody, in nonhuman primates. Regul Toxicol Pharmacol. 2019 Nov;108:104476.

CAS Number: 1326244-10-3

Molecular Weight: 144.4 (kDa)

Compound Purity: 95.00

Research Area: Inflammation/Immunology

Solubility: 10 mM in DMSO

Target: Interleukin Related

• Artikelnummer: MEXHY-P99256-10
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99256-10
• Green Labware: Nein
• Verpackungseinheit: 10 mg
• Mengeneinheit: STK